Assessment and management of heart failure in patients with chronic kidney disease.

[1]  A. Timóteo,et al.  Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis , 2023, Heart Failure Reviews.

[2]  G. Pontone,et al.  Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study , 2023, Journal of clinical medicine.

[3]  Y. Zhang,et al.  Association between serum klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007-2016. , 2022, International journal of cardiology.

[4]  G. Parati,et al.  Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.

[5]  T. Mavrakanas,et al.  Hydralazine–Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis , 2022, Kidney international reports.

[6]  R. Vasan,et al.  Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  G. Pontone,et al.  Coronary-specific quantification of myocardial deformation by strain echocardiography may disclose the culprit vessel in patients with non-ST-segment elevation acute coronary syndrome , 2022, European heart journal open.

[8]  M. Carneiro-Ramos,et al.  Cardiorenal syndrome: long road between kidney and heart , 2022, Heart Failure Reviews.

[9]  aguda y crónica,et al.  Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2022, Revista espanola de cardiologia.

[10]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.

[11]  N. Farré,et al.  Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction. , 2021, Reviews in cardiovascular medicine.

[12]  W. van Biesen,et al.  Free P-Cresyl Sulfate Shows The Highest Association With Cardiovascular Outcome In Chronic Kidney Disease. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  T. Zeller,et al.  Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs , 2020, Frontiers in Cardiovascular Medicine.

[14]  H. Ueyama,et al.  Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure , 2020, Kidney international reports.

[15]  David W. Johnson,et al.  Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Spiros C. Denaxas,et al.  Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure , 2020, Nature Communications.

[17]  D. Andreini,et al.  Multimodality imaging of left atrium in patients with atrial fibrillation. , 2019, Journal of cardiovascular computed tomography.

[18]  H. Tighiouart,et al.  Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. , 2019, Kidney international.

[19]  Mira-Lynn Chavanon,et al.  Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial. , 2019, Biomarkers in medicine.

[20]  Christopher L. Roy,et al.  2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.

[21]  J. Bargman,et al.  Defining the role of peritoneal dialysis in management of congestive heart failure , 2019, Expert review of cardiovascular therapy.

[22]  M. Emdin,et al.  The analysis of left atrial function predicts the severity of functional impairment in chronic heart failure: The FLASH multicenter study. , 2019, International journal of cardiology.

[23]  S. Niemczyk,et al.  Peritoneal Ultrafiltration in the Long-Term Treatment of Chronic Heart Failure Refractory to Pharmacological Therapy , 2019, Front. Physiol..

[24]  A. Remppis,et al.  Peritoneal dialysis as therapeutic option in heart failure patients , 2019, ESC heart failure.

[25]  P. Roberts,et al.  Leadless Pacemaker Implantation in Hemodialysis Patients: Experience With the Micra Transcatheter Pacemaker. , 2019, JACC. Clinical electrophysiology.

[26]  M. Wong,et al.  Leadless Pacing in Hemodialysis Patients. , 2019, JACC. Clinical electrophysiology.

[27]  M. Klintschar,et al.  Fibroblast growth factor 23 is induced by an activated renin–angiotensin–aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  Xiaobin Han,et al.  Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II , 2018, Scientific Reports.

[29]  Dylan L. Steen,et al.  Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA cardiology.

[30]  M. James,et al.  Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists , 2018, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[31]  Wojciech Zareba,et al.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference , 2018, European heart journal.

[32]  G. Filippatos,et al.  Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease , 2018, ESC heart failure.

[33]  L. Lund,et al.  Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction , 2017, European journal of heart failure.

[34]  D. Andreini,et al.  Additional value of inflammatory biomarkers and carotid artery disease in prediction of significant coronary artery disease as assessed by coronary computed tomography angiography , 2017, European heart journal cardiovascular Imaging.

[35]  I. Skoularigis,et al.  Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3 , 2017, Therapeutic advances in cardiovascular disease.

[36]  G. Pontone,et al.  Effect of Coronary Revascularization on the Prognostic Value of Stress Myocardial Contrast Wall Motion and Perfusion Imaging , 2017, Journal of the American Heart Association.

[37]  Masaya Takahashi,et al.  Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. , 2017, Kidney international.

[38]  Luis M. Ruilope,et al.  Renin-angiotensin system blockade: Finerenone. , 2017, Nephrologie & therapeutique.

[39]  David W. Johnson,et al.  Cardiac biomarkers in dialysis , 2016, AIMS Genetics.

[40]  K. Aonuma,et al.  Clinical Implications of Intrarenal Hemodynamic Evaluation by Doppler Ultrasonography in Heart Failure. , 2016, JACC. Heart failure.

[41]  G. Filippatos,et al.  Reframing the association and significance of co‐morbidities in heart failure , 2016, European journal of heart failure.

[42]  I. Komuro,et al.  Utility of Cystatin C for Estimating Glomerular Filtration Rate in Patients With Muscular Dystrophy. , 2016, International heart journal.

[43]  N. Hassanin,et al.  Early Detection of Subclinical Uremic Cardiomyopathy Using Two‐Dimensional Speckle Tracking Echocardiography , 2016, Echocardiography.

[44]  F. Gaita,et al.  Prognostic incremental role of right ventricular function in acute decompensation of advanced chronic heart failure , 2016, European journal of heart failure.

[45]  S. Kutalek,et al.  Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis , 2016, Journal of Interventional Cardiac Electrophysiology.

[46]  C. Parikh,et al.  Amino-Terminal Pro-B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Renal Dysfunction: A Systematic Review and Meta-Analysis. , 2015, JACC. Heart failure.

[47]  D. Freimark,et al.  Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis , 2015, BioMed research international.

[48]  J. Kautzner,et al.  Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. , 2015, JACC. Heart failure.

[49]  S. Rex,et al.  Noninvasive estimation of left atrial pressure with transesophageal echocardiography , 2015, Annals of cardiac anaesthesia.

[50]  K. Damman,et al.  The kidney in heart failure: an update. , 2015, European heart journal.

[51]  N. Abidin,et al.  Cardiac imaging in patients with chronic kidney disease , 2015, Nature Reviews Nephrology.

[52]  J. McMurray,et al.  Terminology and definition of changes renal function in heart failure. , 2014, European heart journal.

[53]  P. Ponikowski,et al.  Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF , 2014, European journal of heart failure.

[54]  C. O'connor,et al.  Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.

[55]  S. Wicky,et al.  The Impact of Transvenous Cardiac Devices on Vascular Access Patency in Hemodialysis Patients , 2013, Seminars in dialysis.

[56]  K. Swedberg,et al.  The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT , 2013, European journal of heart failure.

[57]  M. Rich,et al.  Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. , 2013, International journal of cardiology.

[58]  Satoshi Okayama,et al.  Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. , 2013, Journal of cardiology.

[59]  Yukihito Sato Diagnostic and prognostic property of NT-proBNP in patients with renal dysfunction. , 2013, Journal of cardiology.

[60]  Azra Bihorac,et al.  Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury , 2013, Critical Care.

[61]  R. Leano,et al.  Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[63]  K. Leunissen,et al.  Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[64]  E. Núñez,et al.  Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure , 2012, European journal of heart failure.

[65]  S. Aker,et al.  Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease , 2012, European journal of heart failure.

[66]  C. Ronco,et al.  Cardio-renal syndromes: a systematic approach for consensus definition and classification , 2012, Heart Failure Reviews.

[67]  Thomas H. Marwick,et al.  Use and Limitations of E/e' to Assess Left Ventricular Filling Pressure by Echocardiography , 2011, Journal of cardiovascular ultrasound.

[68]  H. Halperin,et al.  End‐Stage Renal Disease Predicts Complications in Pacemaker and ICD Implants , 2011, Journal of cardiovascular electrophysiology.

[69]  G. Lip,et al.  Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. , 2011, Journal of the American College of Cardiology.

[70]  Bertram Pitt,et al.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial , 2011, European heart journal.

[71]  J. McMurray,et al.  Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) , 2010, European journal of heart failure.

[72]  J. Struck,et al.  Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. , 2009, Journal of the American College of Cardiology.

[73]  B. Fagerberg,et al.  The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). , 2009, Journal of cardiac failure.

[74]  D. Kaye,et al.  Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. , 2008, Journal of cardiac failure.

[75]  W. Mullens,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2008, Journal of the American College of Cardiology.

[76]  G. Fonarow,et al.  High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.

[77]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[78]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[79]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[80]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[81]  G. Bakris,et al.  beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. , 2004, Archives of internal medicine.

[82]  J. Craft Eplerenone (Inspra), a New Aldosterone Antagonist for the Treatment of Systemic Hypertension and Heart Failure , 2004, Proceedings.

[83]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[84]  P. Golino,et al.  Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. , 2003, Journal of the American College of Cardiology.

[85]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  M. Raftery,et al.  A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. , 1994, Kidney international.

[87]  K. Nolph,et al.  [Continuous ambulatory peritoneal dialysis]. , 1978, Polskie Archiwum Medycyny Wewnetrznej.

[88]  Akshay S. Desai,et al.  Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial , 2017, JAMA cardiology.

[89]  J. Cleland,et al.  IVC diameter in patients with chronic heart failure: relationships and prognostic significance. , 2013, JACC. Cardiovascular imaging.

[90]  G. Plosker,et al.  Icodextrin , 2012, Drugs.

[91]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.

[92]  D. Madigan,et al.  Detection of Spironolactone-Associated Hyperkalaemia Following the Randomized Aldactone Evaluation Study (RALES) , 2007, Drug safety.